Home Characteristics and management of mirror syndrome: a systematic review (1956–2016)
Article
Licensed
Unlicensed Requires Authentication

Characteristics and management of mirror syndrome: a systematic review (1956–2016)

  • Sabah Allarakia , Hassan A. Khayat EMAIL logo , Moyassar M. Karami , Abdulaziz M. Aldakhil , Ahmed M. Kashi , Abdulrahman H. Algain , Mohammad A. Khan , Loai S. Alghifees and Raed E. Alsulami
Published/Copyright: March 20, 2017

Abstract

Objectives:

To describe the clinical features of mirror syndrome and to correlate the effects of different treatments with the fetal outcomes.

Data sources:

Online search up to May 2016 was conducted in the PubMed, Embase (Ovid platform) and clinicalTrials.gov without restrictions of language, date or journal. Only papers providing both fetal and maternal presentations and outcomes were included.

Results:

The study included 74 papers (n=111), with an additional two patients diagnosed at our center (n=113). The mean gestational age at diagnosis was 27 weeks±30 days (16–39 weeks). Whether early or late gestational age at diagnosis, and whether mother and fetus show symptoms simultaneously or on different dates, has insignificant impact on fetal outcome (P=0.06 and P=0.46, respectively). Edema (84%) followed by hypertension (60.1%) were the leading maternal findings. Fetal hydrops (94.7%) and placental edema (62.8%) were the commonest sonographic features. Procedures correcting fetal hydrops/anemia in utero as well as labor induction were the only treatment options correlated with improved fetal survival (χ2 analysis, P=0.01 and Fisher’s exact test, P=0.02; respectively). The overall rate of fetal/neonatal mortality was 67.26%.

Conclusion:

The gestational age at diagnosis and sequence of presentation have insignificant impact on fetal outcome. Improved fetal survival was associated with procedural interventions that correct fetal hydrops as well as labor induction.

  1. Disclosure: The authors of this study disclose “no” source of potential support or sponsor names or any financial involvement that represent potential conflict of interest.

    This paper was not part of a presentation/poster at a meeting and has not been considered for publication by any journal.

  2. Author’s statement

  3. Conflict of interest: Authors state no conflict of interest.

  4. Material and methods: Informed consent: Informed consent has been obtained from all individuals included in this study.

  5. Ethical approval: The research related to human subject use has complied with all the relevant national regulations, and institutional policies, and is in accordance with the tenets of the Helsinki Declaration, and has been approved by the authors’ institutional review board or equivalent committee.

References

[1] Kaiser IH. Ballantyne and triple edema. Am J Obstet Gynecol. 1971;110:115–20.10.1016/0002-9378(71)90226-2Search in Google Scholar PubMed

[2] Braun T, Brauer M, Fuchs I, Czernik C, Dudenhausen JW, Henrich W, et al. Mirror syndrome: a systematic review of fetal associated conditions, maternal presentation and perinatal outcome. Fetal Diagn Ther. 2010;27:191–203.10.1159/000305096Search in Google Scholar PubMed

[3] Espinoza J, Romero R, Nien JK, Kusanovic JP, Richani K, Gomez R, et al. A role of the anti-angiogenic factor sVEGFR-1 in the “mirror syndrome” (Ballantyne’s syndrome). J Matern Neonatal Med. 2006;19:607–13.10.1080/14767050600922677Search in Google Scholar PubMed PubMed Central

[4] Goa S, Mimura K, Kakigano A, Tomimatsu T. Normalisation of angiogenic imbalance after intra-uterine transfusion for mirror syndrome caused by parvovirus B19. Fetal Diagn Ther. 2013;34:176–9.10.1159/000348778Search in Google Scholar PubMed

[5] Carbillon L, Oury JF, Guerin JM, Azancot A, Blot P. Clinical biological features of Ballantyne syndrome and the role of placental hydrops. Obstet Gynecol Surv. 1997;52:310–4.10.1097/00006254-199705000-00023Search in Google Scholar PubMed

[6] Prefumo F, Pagani G, Fratelli N, Benigni A, Frusca T. Increased concentrations of antiangiogenic factors in mirror syndrome complicating twin-to-twin transfusion syndrome. Prenat Diagn. 2010;30:378–9.10.1002/pd.2461Search in Google Scholar PubMed

[7] De Oliveira L, Sass N, Boute T, Moron AF. SFlt-1 and PlGF levels in a patient with mirror syndrome related to cytomegalovirus infection. Euro J Obstet Gynecol Repr Bio. 2011;158:366–7.10.1016/j.ejogrb.2011.04.049Search in Google Scholar PubMed

[8] Lee JY, Hwang JY. Mirror syndrome associated with fetal leukemia. J Obstet Gynaecol Res. 2015;41:971–4.10.1111/jog.12654Search in Google Scholar PubMed

[9] Harry W, Clewell WH. Resolution of Ballantyne syndrome following the resolution of fetal hydrops secondary to congenital parvovirus. Ultrasound Obst Gynecol. 2005;26:376–471.10.1002/uog.2563Search in Google Scholar

[10] Heyborne KD, Chism DM. Reversal of Ballantyne syndrome by selective second-trimester fetal termination. A case report. J Reprod Med. 2000; 45:360–2.Search in Google Scholar PubMed

[11] Zhao Y, Liu G, Wang J, Yang J, Shen D, Zhang X. Mirror syndrome in a Chinese hospital: diverse causes and maternal fetal features. J Matern Fetal Neonatal Med. 2013;26:254–8.10.3109/14767058.2012.733765Search in Google Scholar PubMed

[12] Chang YL, Chao AS, Hsu JJ, Chang SD, Soong YK. Selective fetocide reversed mirror syndrome in a dichorionic triplet pregnancy with severe twin-twin transfusion syndrome: a case report. Fetal Diagn Ther. 2007;22:428–30.10.1159/000106348Search in Google Scholar PubMed

[13] Graham N, Garrod A, Bullen P, Heazell AE. Placental expression of anti- angiogenic proteins in mirror syndrome: a case report. Placenta. 2012;33:528–31.10.1016/j.placenta.2012.02.016Search in Google Scholar PubMed

[14] Llurba E, Marsal G, Sanchez O, Dominguez C, Alijotas-Reig J, Carreras E, et al. Angiogenic and antiangiogenic factors before and after resolution of maternal mirror syndrome. Ultrasound Obstet Gynecol. 2012;40:367–9.10.1002/uog.10136Search in Google Scholar PubMed

[15] Rana S, Venkatesha S, DePaepe M, Chien EK, Paglia M, Karumanchi SA. Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol. 2007;109(2 Pt 2):549–52.10.1097/01.AOG.0000248538.03280.cfSearch in Google Scholar PubMed

[16] Stepan H, Renaldo F. Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops. N Engl J Med. 2006;354:1857–8.10.1056/NEJMc052721Search in Google Scholar PubMed

[17] Takahashi H, Matsubara S, Kuwata T, Ohkuchi A, Mukoda Y, Saito K, et al. Maternal manifestation of Ballantyne’s syndrome occurring concomitantly with the development of fetal congenital mesoblastic nephroma. J Obstet Gynaecol Res. 2014;40:1114–7.10.1111/jog.12286Search in Google Scholar PubMed

[18] Vidaeff AC, Pschirrer ER, Mastrobattista JM, Gilstrap LC 3rd, Ramin SM. Mirror syndrome. A case report. J Reprod Med. 2002;47:770–4.Search in Google Scholar PubMed

[19] Hirata G, Aoki S, Sakamaki K, Takahashi T, Hirahara F, Ishikawa H. Clinical characteristics of mirror syndrome: a comparison of 10 cases of mirror syndrome with non-mirror syndrome fetal hydrops cases. J Matern Neonatal Med. 2016;29:2630–4.10.3109/14767058.2015.1095880Search in Google Scholar PubMed


Supplemental Material:

The online version of this article offers supplementary material (DOI: https://doi.org/10.1515/jpm-2016-0422).


Received: 2016-12-27
Accepted: 2017-1-17
Published Online: 2017-3-20
Published in Print: 2017-12-20

©2017 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 5.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jpm-2016-0422/html?lang=en
Scroll to top button